Why does labetalol fail in severe preeclampsia? new study aims to find out
NCT ID NCT07547046
First seen May 02, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
Severe preeclampsia is a dangerous pregnancy complication that can cause high blood pressure, harming both mother and baby. This observational study will follow 350 women to identify factors that make blood pressure control with the drug labetalol fail. By understanding these factors, doctors hope to predict treatment failure and adjust care more quickly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE PREECLAMPSIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH Agen-Nerac
Nérac, France
Contact
-
CH de Roubaix
Roubaix, France
Contact Email: •••••@•••••
-
CHRU Nancy
Nancy, France
Contact Email: •••••@•••••
-
CHU Bordeaux
Bordeaux, France
Contact
-
CHU Carémeau
Nîmes, France
Contact
-
CHU Clermont-Ferrand
Clermont-Ferrand, France
Contact Email: •••••@•••••
-
CHU Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant
Lyon, France
Contact
-
CHU Lille
Lille, France
Contact Email: •••••@•••••
-
CHU Martinique
Martigues, France
Contact Email: •••••@•••••
-
Hôpital Antoine Béclère
Clamart, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Armand-Trousseau
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Bicêtre
Le Kremlin-Bicêtre, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Cochin Port Royal
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital Necker
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
labetalol
What this could lead to
If successful, this study could help doctors identify which women with severe preeclampsia are less likely to respond to labetalol, allowing for faster, more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new therapy. It may only identify associations, not causes, and results may not apply to all populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.